These gala-series GSLs are, in fact, expected to be elevated in Fabry disease, as they also contain the terminal Gal(α 1→4)Gal carbohydrate chain that is recognized by α-gal A. While galabiosylceramides may contribute to the DHC measurements in kidney, this is unlikely the case in other tissues, given that DHC storage was limited in these tissues. The gene discussed is GAL; the disease is Fabry disease.